Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064337 · ClinicalTrials.gov registry record · Phase 2
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00064337 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 104 participants.
The verdict
NCT00064337, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloidosis.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG melphalan
- BIOLOGICAL filgrastim
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2004-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064337
The ClinicalTrials.gov registry entry for NCT00064337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00064337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064337 about?
NCT00064337 is a clinical study titled "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis". RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer c...
What is the current status of trial NCT00064337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2004-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00064337?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00064337?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.